In Soo Oh1,2, Dong Hyun Sinn3, Tae Wook Kang4, Min Woo Lee4, Wonseok Kang1, Geum-Youn Gwak1, Yong-Han Paik1, Moon Seok Choi1, Joon Hyeok Lee1, Kwang Cheol Koh1, Seung Woon Paik1. 1. Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, 81 Irwon-ro, Gangnam-gu, Seoul, 06351, Korea. 2. Department of Internal Medicine, National Police Hospital, Seoul, Korea. 3. Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, 81 Irwon-ro, Gangnam-gu, Seoul, 06351, Korea. sinndhn@hanmail.net. 4. Department of Radiology and Center for Imaging Science, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea.
Abstract
BACKGROUND/AIM: Assessment of liver function is essential for management of hepatocellular carcinoma (HCC). Recently, albumin-bilirubin (ALBI) grade has been reported as a useful tool for assessing hepatic reserve in patients with HCC. The objective of this study was to determine whether ALBI grade could be used to predict the overall survival of very early-stage HCC patients treated with radiofrequency ablation (RF ablation). METHODS: A cohort of 368 patients with very early-stage HCC treated with RF ablation was retrospectively analyzed. The overall survival and recurrence-free survival were calculated in groups classified by ALBI grade and Child-Pugh score. RESULTS: Overall survival of patients with ALBI grade 1 was better than that of patients with ALBI grade 2 (5-year survival rate 88.5 vs. 73.8%, P < 0.001). In multivariable-adjusted model, ALBI grade was found to be an independent factor associated with overall survival (hazard ratio 2.44; 95% confidence interval 1.43-4.15). ALBI grade was able to stratify patients with distinct overall survival among patients within the same Child-Pugh score (5-year survival rate for Child-Pugh score 5: 88.5 vs. 76.6%, P = 0.002; for Child-Pugh score 6: 88.9 vs. 70.1%, P = 0.064). In contrast, Child-Pugh score was unable to stratify patients with distinct overall survival within the same ALBI grade. CONCLUSIONS: Among patients with very early-stage HCC treated with RF ablation, ALBI grade was a good stratifying biomarker. ALBI grade was better tool for assessing liver function than Child-Pugh score for very early-stage HCC treated with RF ablation.
BACKGROUND/AIM: Assessment of liver function is essential for management of hepatocellular carcinoma (HCC). Recently, albumin-bilirubin (ALBI) grade has been reported as a useful tool for assessing hepatic reserve in patients with HCC. The objective of this study was to determine whether ALBI grade could be used to predict the overall survival of very early-stage HCC patients treated with radiofrequency ablation (RF ablation). METHODS: A cohort of 368 patients with very early-stage HCC treated with RF ablation was retrospectively analyzed. The overall survival and recurrence-free survival were calculated in groups classified by ALBI grade and Child-Pugh score. RESULTS: Overall survival of patients with ALBI grade 1 was better than that of patients with ALBI grade 2 (5-year survival rate 88.5 vs. 73.8%, P < 0.001). In multivariable-adjusted model, ALBI grade was found to be an independent factor associated with overall survival (hazard ratio 2.44; 95% confidence interval 1.43-4.15). ALBI grade was able to stratify patients with distinct overall survival among patients within the same Child-Pugh score (5-year survival rate for Child-Pugh score 5: 88.5 vs. 76.6%, P = 0.002; for Child-Pugh score 6: 88.9 vs. 70.1%, P = 0.064). In contrast, Child-Pugh score was unable to stratify patients with distinct overall survival within the same ALBI grade. CONCLUSIONS: Among patients with very early-stage HCC treated with RF ablation, ALBI grade was a good stratifying biomarker. ALBI grade was better tool for assessing liver function than Child-Pugh score for very early-stage HCC treated with RF ablation.
Authors: Anthony W H Chan; Takshi Kumada; Hidenori Toyoda; Toshifumi Tada; Charing C N Chong; Frankie K F Mo; Winnie Yeo; Philip J Johnson; Paul B S Lai; Anthony T C Chan; Ka-Fai To; Stephen L Chan Journal: J Gastroenterol Hepatol Date: 2016-07 Impact factor: 4.029
Authors: D J Pinato; C Yen; D Bettinger; R Ramaswami; T Arizumi; C Ward; M Pirisi; M E Burlone; R Thimme; M Kudo; R Sharma Journal: Aliment Pharmacol Ther Date: 2017-01-24 Impact factor: 8.171
Authors: Philip J Johnson; Sarah Berhane; Chiaki Kagebayashi; Shinji Satomura; Mabel Teng; Helen L Reeves; James O'Beirne; Richard Fox; Anna Skowronska; Daniel Palmer; Winnie Yeo; Frankie Mo; Paul Lai; Mercedes Iñarrairaegui; Stephen L Chan; Bruno Sangro; Rebecca Miksad; Toshifumi Tada; Takashi Kumada; Hidenori Toyoda Journal: J Clin Oncol Date: 2014-12-15 Impact factor: 44.544
Authors: Alessandro Vitale; Markus Peck-Radosavljevic; Edoardo G Giannini; Eric Vibert; Wolfgang Sieghart; Sven Van Poucke; Timothy M Pawlik Journal: J Hepatol Date: 2016-09-24 Impact factor: 25.083
Authors: Nicole Bernardi; Marcio F Chedid; Tomaz J M Grezzana-Filho; Aljamir D Chedid; Marcelo A Pinto; Ian Leipnitz; João E Prediger; Carolina Prediger; Ariane N Backes; Thais O Hammes; Lea T Guerra; Alexandre de Araujo; Mario R Alvares-da-Silva; Cleber R P Kruel Journal: Dig Dis Sci Date: 2019-01-14 Impact factor: 3.199
Authors: D Pereyra; B Rumpf; M Ammann; S F Perrodin; D Tamandl; C Haselmann; J Stift; C Brostjan; F Laengle; G Beldi; T Gruenberger; P Starlinger Journal: Ann Surg Oncol Date: 2019-01-07 Impact factor: 5.344